Head-to-head · WeighScore
Genesis Health vs GoodRx
The verdict
GoodRx takes it — 69.6/100 to 67.9/100, but only just.
GoodRx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. GoodRx (NASDAQ: GDRX) is the largest US prescription savings platform. Genesis Health is close behind and may still be the better fit — see the factor split below.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Genesis Health | GoodRx |
|---|---|---|
| WeighScore | 67.9/100 | 69.6/100 |
| Grade | C | C |
| Scorecard rank | #160 | #125 |
| Semaglutide | $175/mo (starting dose, compounded) | Not disclosed |
| Tirzepatide | $235/mo (starting dose, compounded) | $299/mo (brand Zepbound) |
| Coverage | Coverage not published | All 50 states |
| Brand-name access | Yes | Yes |
| Oral / sublingual | Injection only | Injection only |
Graded #160 · C
Strengths
- Annual plan as low as $99/mo for semaglutide or $125/mo for tirzepatide
- Offers both compounded and brand-name GLP-1s (Wegovy, Ozempic, Zepbound) in one platform
- Includes health coaching, active community, and free expedited shipping on every plan
- LegitScript certified; medications sourced from audited, licensed US compounding pharmacies
- Same-day provider visits, personalized dosing, and 24/7 care team messaging
Where it loses points
- States served not publicly listed; telehealth coverage unconfirmed for all states
- Monthly starting price ($175 sema / $235 tirz) is mid-market without annual commitment
- Labs not disclosed or included in any published plan tier
- Brand-name GLP-1 pricing not published; insurance or coupon required
- Compounded medications are not FDA-approved
Graded #125 · C
Strengths
- $149/month self-pay for brand-name Foundayo (orforglipron) — matches the lowest cash price at launch, far below typical retail
- $299/month self-pay for Zepbound KwikPen — well under Lilly's typical cash list price
- Honored at 70,000+ US pharmacies — the largest retail redemption network of any GLP-1 channel we cover
- No membership fee — bring your own prescription and present the discount card at the pharmacy counter
- Brand-name FDA-approved medication, not compounded
Where it loses points
- Requires a valid prescription — GoodRx is a discount card, not a prescriber; you still need a clinician to write the script
- Self-pay only — does not apply toward insurance benefits or deductibles
- Headline price applies to the lowest Foundayo dose; higher doses may cost more
- No compounded GLP-1 options — not the channel for compounded semaglutide or tirzepatide
- Pricing can change as Lilly's manufacturer coupon program evolves
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.